thioredoxin related transmembrane protein 4Genealiases: DJ971N18.2 · PDIA14 · TXNDC13
Q-omics provides the consensus-scored TMX4 profile across patient tissues and cancer cell-line models. TMX4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TMX4 is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, TMX4 protein abundance shows 21,648 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LUAD, LUSC, and PDAC as cancer lineages where TMX4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMX4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMX4 survival associations across molecular data types. TMX4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMX4 RNA expression–survival associations across cancer types. High TMX4 expression shows unfavorable associations in UVM and LUSC, but favorable associations in LUAD, KIRC, PAAD and UCEC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for TMX4 RNA expression.
This table summarizes TMX4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in LUSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMX4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMX4 shows lower tumor expression in LUSC, BLCA, UCEC, BRCA and THCA and higher tumor expression in LIHC. The LUSC box plot shows higher TMX4 RNA expression in normal versus tumor tissue (log2 FC = −1.513, t-test p < 0.001).
This table shows molecular features associated with TMX4 in patient tissues and cancer cell lines. In patient samples, TMX4 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMX4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
